CV Sciences Inc (CVSI)

[Mr Fox]

Q4 2017 and 2017 Full Year - Operating Highlights

Record Q1 2018 Sales of $8,071,000, an increase of 114% compared to Q1 2017
Record Q1 2018 Gross Profit of $5,562,000, an increase of 129% compared to Q1 2017
Record Q1 2018 GAAP Net Income of $619,000, an improvement of $4,404,000 when compared to Q1 2017
Record Q1 2018 Cash Flow from Operations of $1,654,000, an improvement of $1,628,000 when compared to Q1 2017
Record Q1 2018 Adjusted EBITDA of $1,822,000, an improvement of $2,012,000 when compared to Q1 2017

Increased Retail Channel Distribution to 1,771 Stores as of March 31, 2018, an increase of 14% compared to three months ago at December 31, 2017
Continued Progress in Drug Development Division including preclinical progress with CVSI-007, the Company’s patent pending synthetic-based cannabidiol, which will be co-administered with nicotine to provide treatment options for smokeless tobacco use and addiction, currently a multibillion market with no currently FDA-approved drugs available to help patients.